Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
European Journal of Haematology|August 19, 2024
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantationSara Redondo, Irene García-Cadenas, Albert Esquirol, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 15, 2017
Do Patients and Physicians Agree When They Assess Quality of Life?Anna Barata, Rodrigo Martino, Ignasi Gich, et al.
British Journal of Haematology|June 26, 2013
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomasCristina Bertolo, Sergio Roa, Ainara Sagardoy, et al.
European Journal of Haematology|April 14, 2023
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBISara Redondo, Irene García-Cadenas, Antonio Vila, et al.
European Journal of Haematology|July 23, 2025
Standard Versus Reduced-Doses of Post-Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell TransplantationSara Redondo, Irene García-Cadenas, Albert Esquirol, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradicationFrancesc Bosch, Ana Ferrer, Neus Villamor, et al.
British Journal of Haematology|May 18, 2016
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapyCarmen Martínez, Antonio Díaz-López, Mercedes Rodriguez-Calvillo, et al.
Blood Advances|September 28, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphomaMichael Dickinson, Javier Briones, Alex F Herrera, et al.
Hemasphere|September 15, 2021
The EHA Research Roadmap: Immune-based Therapies for Hematological MalignanciesHermann Einsele, Javier Briones, Fabio Ciceri, et al.
Pageof 11